| Today's Big NewsApr 5, 2023 |
| By Annalee Armstrong Ginkgo Bioworks doesn’t want the biotech industry’s therapies. But it does want the platforms that create them, which is why the cell programming company is buying up StrideBio for its gene therapy platform. |
|
|
|
By Annalee Armstrong A new community-generated data resource from Pillar VC, the Founder-led Biotech Summit and compensation analysis firm Pave seeks to take the guesswork out of the process by summarizing salary ranges from 90 companies. |
By Max Bayer Proxygen has inked a third licensing deal in less than 30 months, singing on agreement with Merck & Co. worth more than $2.5 billion. The Austrian biotech is not disclosing how many targets the deal is for. |
By Annalee Armstrong NGM Bio’s webpage declares "We're Hiring!" but a peek at the investor relations section of the biotech’s website tells a different—and sobering—story. |
By Max Bayer AI Therapeutics is touting new phase 2 data of its ALS med, saying data found the med was safe and produced encouraging results in a biomarker for the disease. The biotech's CEO said the company plans to launch another trial in 2024. |
By Gabrielle Masson The Alzheimer’s Drug Discovery Foundation, formed 25 years ago in honor of cosmetic business tycoon Estée Lauder, just received $200 million from the Lauder family—the nonprofit’s largest donation ever. |
By Nick Paul Taylor Immunic can no longer keep all its balls in the air. Rather than keep advancing on three fronts, the firm has decided to deprioritize development in psoriasis and castration-resistant prostate cancer and throw its remaining resources at two other programs. |
By James Waldron You wait months for a molecular glue degrader licensing deal, and then two come along at once. At the same moment that Merck & Co. revealed it’s signed up to explore the modality with Austria’s Proxygen, a similar announcement has been made by Incyte. |
By Nick Paul Taylor BenevolentAI’s hopes of outlicensing its atopic dermatitis candidate this year have taken a hit. In a phase 2b trial, the topical pan-Trk inhibitor failed to improve eczema symptoms or itch, denting the prospects of the program and raising questions about the AI-enabled model that proposed the approach. |
By Joseph Keenan Concept Life Sciences, a U.K.-based CRO, was acquired by Limerston Capital for an undisclosed amount, marking the fourth life sciences platform deal for the investment firm. |
By Joseph Keenan Swedish patient enrollment company Trialbee has inked a partnership with Savvy Cooperative, which describes itself as the first and only patient-owned public benefit co-op. |
By Teresa Carey This week on "Podnosis," we discuss the rising tide of mental health concerns among young people. We also talk about how inflation and labor shortages will play out in Medicare Advantage. |
By Andrea Park Try as Philips might to forge a path out of its two-year-long saga of a slew of respiratory device recalls, the company is facing yet another—linked to more than 62,000 of its ventilators. |
By Kevin Dunleavy AstraZeneca is touting the results of a phase 3 trial in patients with newly diagnosed ovarian cancer who have advanced disease but no BRCA mutations. An interim analysis of the DUO-O study showed that a combination of AZ’s Lynparza and Imfinzi, added to chemotherapy and bevacizumab, significantly improved progression-free survival. |
By Paige Minemyer The NCAA basketball tournament is officially underway, and that means the Fierce Healthcare team is back with another bracket competition as well. |
By Ben Adams Intra-Cellular’s 2022 commercial for its bipolar depression therapy Caplyta “Let in the Lyte” has been crowned this year’s winner. |
By Angus Liu,Eric Sagonowsky After already spending billions to defend itself against claims its talc products cause cancer, J&J is moving to end the litigation altogether. But lawyers for some plaintiffs have said the offer is "woefully inadequate." |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss how 2023 is shaping up to be much the same as last year when it comes to financing trends for biotechs. We also cover Emergent's Narcan winning the first over-the-counter approval for an opioid-overdose drug and more of this week's top headlines. |
|
|---|
|
|
| Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
